Clinical implications of monitoring circulating tumor DNA in early- and late-stage non-small cell lung cancer patients.

person Muyun Peng The Second Xiangya Hospital of Central South University, Changsha, China info_outline Muyun Peng, Lihan Chin, Qi Huang, Wei Yin, Sichuang Tan, Chen Chen, Wenliang Liu, Jingqun Tang, Xiang Wang, Lientu Wang, Fenglei Yu

Authors person Muyun Peng The Second Xiangya Hospital of Central South University, Changsha, China info_outline Muyun Peng, Lihan Chin, Qi Huang, Wei Yin, Sichuang Tan, Chen Chen, Wenliang Liu, Jingqun Tang, Xiang Wang, Lientu Wang, Fenglei Yu Organizations The Second Xiangya Hospital of Central South University, Changsha, China, Berry Oncology, Beijing, China, Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China Abstract Disclosures Research Funding Other Foundation Background: Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers, and the most common types of NSCLC are squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. The development of noninvasive methods to monitor circulating tumor DNA (ctDNA) continues to be a major challenge in NSCLC. Methods: We investigated if detection of ctDNA after resection of NSCLC identifies the patients with risk of relapse, and furthermore, informs about response to management.In this cohort study, high-throughput 168 target-gene capture technology and high-sensitivity circulating single molecule amplification and re-sequencing technology (cSMART) were used to detect the somatic mutations in tissues and plasma of patients with NSCLC, respectively. Moreover, ctDNA somatic mutations were used to monitor changes in minimal residual disease during a follow-up period. Results: A total of 169 patients with lung squamous cell carcinoma and adenocarcinoma were included. Detectable levels of ctDNA were present in 60.7% of patients with stage I and 68.8% of patients with late-stage. In patients not treated with adjuvant chemotherapy, ctDNA was detected preoperatively in 46 of 81 (56.8%) patients, 14 (30.4%) of whom had recurred at follow-up of 44 months; recurrence occurred in only 2 (5.7 %) of 35 patients with negative ctDNA. Serial ctDNA status changed from positive to negative during the initial phase of post operation in four patients. Then, ctDNA became positive again after 2 weeks to 3 months, all the four patients with relapse during the follow-up of 44 months. Conclusions: Detection of ctDNA supplies evidence of residual disease and identifies patients at risk of relapse. These observations have implications for the intervention of lung squamous cell carcinoma and adenocarcinoma patients.